Panel discussion on...
Pet Supplements
Dr Leah Bessa
Co-Founder & CSO, De Novo Foodlabs

Member of AgroFOOD Industry Hi Tech's Scientific Advisory Board

In this Panel Discussion, several prominent companies within the food and nutraceutical ingredient industry have been invited to discuss about drivers and barriers of healthy lifestyle, focusing on global and regional consumer trends, scientific achievements, emerging delivery formats, use of AI technologies and the implementation of the United Nations sustainability goals.
1B) Human data is an excellent starting point, but it is not sufficient for a final formulation.
Some ingredients that are safe for humans can be inert or even toxic to pets (e.g., xylitol or certain essential oils).
Cats, as obligate carnivores, have unique liver enzyme pathways that change how they process botanicals and fats compared to humans or dogs. There is a critical shortage of feline-specific research; many “pet” supplements are actually “dog” supplements repackaged, leading to poor efficacy in cats.
1E)Owners want to see the “farm-to-bowl” journey, often verified via QR codes on packaging. There is also a massive shift toward alternative proteins (insect, algae, or lab-grown) and upcycled ingredients to reduce the carbon pawprint.
Formulations are beginning to shed “hidden” ingredients like magnesium stearate or artificial palatants in favour of whole-food functional bases like pumpkin or cold-pressed oils.
Even manufacturers are pushing for sustainable ingredients, where they are looking to switch out some of their animal based products for ingredients like spent yeast - due to their sustainability commitments.
2A) The “cleaner” the label, the challenge comes into mask the bitter taste of active botanicals or minerals. Cats are particularly fussy when it comes to unpleasant taste or textures, making liquid or powder-toppers more successful than hard tablets.
High-heat extrusion (kibble) destroys many bioactives. Manufacturers are pivoting to cold-pressing, freeze-drying, or dual-chamber packaging to keep actives stable until the moment of consumption, which can increase the cost for the end consumer.
With a move to including sustainable ’side streams/upcycling’ from the food industry, it creates variability in the input for formulations.
2D)Smaller breeds have faster metabolisms but smaller mouths; mini-chews with high nutrient density are required. They are also smaller in body weight, and require far lower doses of bioactive than larger breeds.
The “Senior” category is the fastest-growing segment, requiring formulations that address multiple comorbidities (e.g., cognitive support + joint health) in one easy-to-digest format. In addition, as pets get older, they require slightly different formats of food ie softer to chew, more palatable etc
4A) Credibility will be key, as we move towards more standardisation and defined by Third-Party Validation of ingredients and their functionality. Brands that invest in peer-reviewed, published clinical trials on their specific finished product (not just the raw ingredients) will dominate.
Supplements that are “Prescription-Grade” and recommended by vets will have the longest lifecycle.
4B) Currently, the gap between regulatory bodies for pet food globally. A global, standardized “Bioactive Certification” that mandates potency testing at the end of shelf-life (rather than just at manufacture) would instantly eliminate low-quality actors and solidify consumer trust.
Panelists
References and notes
- Kovalkovičová, N et al. 2009. Some food toxic for pets. Interdiscip Toxicol. 2(3):169–176. https://doi.org/10.2478/v10102-009-0012-4
- Beleć, K et al. 2025. The Effect of the Type and Concentration of Garlic (Allium sativum) on Heinz Body Concentrations in Canine Erythrocytes—An In Vitro Study. Animals, 15, 3188. https://doi.org/10.3390/ani15213188
- Benyacoub, J. et al. 2003. Supplementation of Food with Enterococcus faecium (SF68) Stimulates Immune Functions in Young Dogs. J. Nutr. 133: 1158-62. https://doi.org/10.1093/jn/133.4.1158
- Bednorz, C. et al. 2013. Feeding the Probiotic Enterococcus faecium Strain NCIMB 10415 to Piglets Specifically Reduces the Number of Escherichia coli Pathotypes That Adhere to the Gut Mucosa. Appl. Environ. Microbiol. 79(24):7896-7904. https://doi.org/10.1128/AEM.03138-13
- Benvenuti, L. et al. 2023. Dietary Supplementation with the Probiotic SF68 Reinforces Intestinal Epithelial Barrier in Obese Mice by Improving Butyrate Bioavailability. Mol. Nutr. Food Res. 67(13): 2200442. https://doi.org/10.1002/mnfr.202200442
- Beirão, B. C. B. et al. 2018. Effect of an Enterococcus faecium probiotic on specific IgA following live Salmonella Enteritidis vaccination of layer chickens. Avian Pathology, 47(3), pp. 325–333. https://doi.org/10.1080/03079457.2018.1450487
- Bybee, S. N. et al. 2011. Effect of the Probiotic Enterococcus faecium SF68 on Presence of Diarrhea in Cats and Dogs Housed in an Animal Shelter. J Vet Intern Med. Jul-Aug;25(4):856-60. https://doi.org/10.1111/j.1939-1676.2011.0738.x
- Regulation - 1831/2003 - EN - EUR-Lex
Questions
1.
2.
3.
4.
Ingredients companies - clinical data
A) What are the main scientific gaps that still exist in PET supplement development compared to human dietary supplements?
B) How important is species-specific research when selecting and developing active ingredients for pets? Can human data ever be sufficient?
C) Is the humanization of pets helping consumers make better-informed choices, or does it risk creating unrealistic expectations about supplement performance?
D) From an ingredient supplier’s perspective, which quality parameters (standardization, bioavailability, purity) are most critical for PET applications?
E) How are trends such as “clean label,” sustainability, and transparency influencing pet owners’ purchasing decisions in the PET supplement space?
F) What type of clinical evidence should realistically be expected to support PET supplement claims today?
G) Which types of claims are most likely to be misunderstood by consumers, and how can this risk be reduced through clearer substantiation and labeling?
H) What are the main methodological challenges in conducting clinical trials for companion animals, and how can they be addressed?
I) How reliable are owner-reported outcomes compared to veterinary assessments, and how should they be integrated into study design?
L) Have you noticed an increasing trend in the use of one (or more) ingredients for pet supplements formulated to promote healthy ageing?
Formulation
A) What are the biggest formulation challenges in PET supplements, particularly regarding palatability, stability, and dosing accuracy?
B) How do formulation choices (e.g., chews, powders, liquids) influence compliance and consistent use from a consumer perspective?
C) Do you see a shift toward simpler, single-ingredient formulations, or are multi-active blends still the dominant approach? Why?
D) How do species differences (dogs vs cats, size, age) influence formulation strategies?
E) Omega 3 alternatives for pet nutrition and sustainability: how do the innovative omega-3s for pet food stack up against their traditional fishy counterparts?
Regulation
A) How do regulatory frameworks for PET supplements differ between the EU and the US, and what challenges do these differences create for global brands?
B) Which types of claims represent the highest regulatory risk today, and which are more likely to be acceptable if properly substantiated?
C) Do you expect regulatory oversight of PET supplements to become stricter in the coming years? Why or why not?
D) What role should veterinarians play in guiding pet owners’ choices regarding PET supplements, and how can trust between brands, vets, and consumers be strengthened?
Open questions
A) Looking ahead 5–10 years, what will be the key factors determining the credibility and long-term success of the PET supplements sector?
B) In your view, what single change—scientific, regulatory, or educational—would most improve consumer trust in PET supplements over the next decade?
References and notes










